Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: RE: Why the focus only on the J3? - dys1

RE: Why the focus only on the J3? - dys1

posted on Mar 12, 2006 06:15AM
``Now to my favorite object of thought - please stop the dividends and start the share buy-back program! The other benefit to shareholdrs, beyond the ones I`ve mentioned previously, is the fact that WE, the shareholders, could then determine WHEN we want our reward (with the assumption that a reduced float will inherently improve the PPS - beyond the dividend amounts I strongly suspect).``

SGE...well stated. Absolutely agree with you on this one! Dividends definitely hurt the shorts, which hopefully is why management is paying the dividends. But....with 305M outstanding shares (as per Yahoo), the PPS has a slim chance of hitting double digits. I keep seeing comparisons to Rambus, well Rambus only has 100M outstanding shares. When PTSC hit $7/share in 2000, how many outstanding shares did they have then? I posed this question and got two responses, 25M and 50M. Well, if you do the math, we are currently trading at either (in 2000 numbers) $20.28 or $10.14 depending on what the actual number of outstanding shares were. Different day, different company. Today we have money coming in, but the street expected revenues back than, so the evaluation should have been the same.

Share
New Message
Please login to post a reply